Bone Lab Dresden


Maintaining lifelong bone health remains a challenge. Therefore, our team works on several research projects linking bone research with diabetes, hematology, immunology, endocrinology, oncology, and materials science. Through our research, we expect to translate bone discoveries into more effective therapies for patients.

Learn more

Research Fields


Check out our current and future research fields

Research Blog & News

Strong bones and less fat

Strong bones and less fat – Scientists from Dresden and Leipzig identify novel molecular switch of bone and energy metabolism


Dresden, 09.11.2018

The formation of bone and fat is very much interdependent as both tissues originate from the same type of progenitor cells: mesenchymal stem cells. These either evolve into osteoblast, cells that build up bone mass, or into adipocytes, fat cells, respectively. Factors supporting the formation of fat tissue inhibit bone regeneration at the same time and thereby negatively impact bone quality.

A team of scientists from the Universities of Dresden, Leipzig and Ulm has now identified a novel protein controlling this interaction in a study recently published in Science Translational Medicine. CD90/Thy-1, as the protein is named, enhances bone regeneration, while concurrently inhibiting the accumulation of fat tissue. Mice lacking this protein have brittle bone and grow fatter. Furthermore, the scientists showed that both patients with osteoporosis and patients who are overweight exhibit lower serum levels of CD90/Thy-1 than healthy patients. Further investigations will likely reveal, whether this factor can be applied to improve bone quality in patients with overweight in future, or act as a marker for early diagnosis of bone loss.

Further information: Press release

Original publication in Science Translation Medicine: “Thy-1 (CD90) promotes bone formation and protects against obesity“, Doi:10.1126/scitranslmed.aao680.


Bone health is a crucial factor to assure quality of life


Dresden, 01.11.2018

A novel review of Tilman Rachner describes how adjuvant endocrine therapies of breast and prostate cancer impair bone health to reduce risk of fracture. Preservation of bone health still remains a long-term clinical challenge in patients with breast and prostate cancer. Dr. Rachner emphasizes: “Each patient receiving endocrine therapy should be stringently assessed for their individual fracture risk when therapy is initiated, and this risk should be reassessed in adequate intervals or whenever major changes to disease status or treatment occur.”

Bone health during endocrine therapy for cancer, Tilman D Rachner, Robert Coleman, Peyman Hadji, Lorenz C Hofbauer, 2018

More information

μBONE – Colonization and Interactions of Tumor Cells within the Bone Microenvironment


Dresden, 01.10.2018

A Germany-wide consortium of cancer and bone scientists started its work on studying the initial colonization of bone by tumor cells and the early interaction with bone cells. To obtain mechanistic insights into these questions, the consortium focusses on breast and prostate cancer. The µbone research alliance will tackle the knowledge gap on bone metastases and reveal innovative mechanistic concepts of bone-tumor interactions for subsequent studies to prevent or cure bone metastases.

More information
More Research news



Bone Lab Dresden
Medizinische Klinik und Poliklinik III
Universitätsklinikum Carl Gustav Carus Dresden
Phone: +49 (0)351 458-3173
eMail: info@bone-lab.de
Fetscherstraße 74 · 01307 Dresden · Germany